• Juju Shang, Shenglei Qiu, Yingjie Zhou, Sina Liu, Zi Wang, Xiaolei Lai, Hongxu Liu, Mingxue Zhou, Zhenmin Zhang, Pengyu Liu, Fangfang Zhang, and Xianghui Meng.
• Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China.
• Medicine (Baltimore). 2022 Nov 25; 101 (47): e31680e31680.

IntroductionAcute myocardial infarction (AMI) is a common cause of death worldwide and heart failure (HF) is the main complication. Although the increase in percutaneous coronary intervention and drug treatment can reduce in-hospital mortality after AMI, the incidence of HF after AMI and the resulting risk of death are still rising, which causes difficulties in the rehabilitation of AMI patients after reperfusion.MethodsIn this prospective, multicenter, randomized, double-blind, double-dummy, placebo-controlled trial, we will assigned 673 eligible patients with AMI after reperfusion into 4 groups: receiving Nao-Xin-Tong capsule (NXT), Bu-Yang-Huan-Wu (BYHW) granule (BYHW), Yang-Yin-Tong-Nao granule (YYTN), or placebo. The course of treatment will be 3 months. The primary outcome is HF incidence within 180 days. Nao-Xin-Tong capsule, BYHW granule, and Yang-Yin-Tong-Nao granule are different traditional Chinese medicines used for tonifying Qi and activating blood (TQAB).ResultsThree months of TQAB combined with Western medicine may reduce the incidence of HF after reperfusion of AMI and improve patients' quality of life.DiscussionThis study will provide an important basis for the application of traditional Chinese medicine in patients with AMI after reperfusion and provide an evidence-based basis for the prevention and treatment strategy of HF after AMI.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

14 keywords...

hide…